JP2005525329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525329A5 JP2005525329A5 JP2003565495A JP2003565495A JP2005525329A5 JP 2005525329 A5 JP2005525329 A5 JP 2005525329A5 JP 2003565495 A JP2003565495 A JP 2003565495A JP 2003565495 A JP2003565495 A JP 2003565495A JP 2005525329 A5 JP2005525329 A5 JP 2005525329A5
- Authority
- JP
- Japan
- Prior art keywords
- selenium
- day
- daily dose
- medicament
- clozapine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 19
- 229910052711 selenium Inorganic materials 0.000 claims 18
- 239000011669 selenium Substances 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 11
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 6
- 229960004170 clozapine Drugs 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 claims 1
- 239000003118 drug derivative Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229940082569 selenite Drugs 0.000 claims 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 claims 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims 1
- 229940055619 selenocysteine Drugs 0.000 claims 1
- 235000016491 selenocysteine Nutrition 0.000 claims 1
- 229960002718 selenomethionine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0202900.7A GB0202900D0 (en) | 2002-02-07 | 2002-02-07 | Novel formulations of drugs |
| PCT/GB2003/000490 WO2003066071A1 (en) | 2002-02-07 | 2003-02-04 | Formulations comprising psychotropic drugs and selenium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525329A JP2005525329A (ja) | 2005-08-25 |
| JP2005525329A5 true JP2005525329A5 (enExample) | 2005-12-22 |
Family
ID=9930626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565495A Pending JP2005525329A (ja) | 2002-02-07 | 2003-02-04 | 向精神薬とセレンから成る配合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6919330B2 (enExample) |
| EP (1) | EP1478374A1 (enExample) |
| JP (1) | JP2005525329A (enExample) |
| AU (1) | AU2003244454A1 (enExample) |
| GB (1) | GB0202900D0 (enExample) |
| NZ (1) | NZ534304A (enExample) |
| TW (1) | TW200404558A (enExample) |
| WO (1) | WO2003066071A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1610791T3 (pl) * | 2003-03-31 | 2011-07-29 | Titan Pharmaceuticals Inc | Wszczepialne urządzenie polimerowe do przedłużonego uwalniania agonisty dopaminy |
| NZ527142A (en) | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| US7071879B2 (en) | 2004-06-01 | 2006-07-04 | Ems Technologies Canada, Ltd. | Dielectric-resonator array antenna system |
| FR2873376B1 (fr) * | 2004-07-23 | 2006-11-24 | Tetrahedron Sas | Nouveaux seleno-hydroxyacides et leurs derives, applications en nutrition, cosmetique et pharmacie |
| US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| WO2006036686A2 (en) * | 2004-09-24 | 2006-04-06 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| EP1803460B1 (en) * | 2004-10-05 | 2012-08-22 | Inovex Co., Ltd. | Use of a platinum colloid containing aqueous solution for the treatment of psychiatric symptoms |
| US8865763B2 (en) | 2005-10-14 | 2014-10-21 | Alltech, Inc. | Methods and compositions for altering cell function |
| AU2005227420B2 (en) * | 2005-10-14 | 2013-05-09 | Alltech, Inc. | Method and compositions for altering cell function |
| US8871715B2 (en) | 2005-10-14 | 2014-10-28 | Alltech, Inc. | Use of selenium compounds, especially selenium yeasts for altering cognitive function |
| MX2008012479A (es) | 2006-03-29 | 2009-08-13 | Velacor Therapeutics Pty Ltd | Tratamiento de enfermedades neurodegenerativas. |
| WO2007127273A2 (en) * | 2006-04-24 | 2007-11-08 | Alltech, Inc. | Methods and compositions for altering cell function |
| WO2008119109A1 (en) | 2007-03-29 | 2008-10-09 | Velacor Therapeutics Pty Ltd | Treatment of neurological disorders |
| WO2009043106A1 (en) * | 2007-10-03 | 2009-04-09 | Velacor Therapeutics Pty Ltd | Inorganic selenium and angiogenesis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090414A (en) * | 1970-05-20 | 2000-07-18 | Life Science Labs, Inc. | Method and composition to reduce cancer incidence |
| SE7812170L (sv) * | 1977-12-07 | 1979-06-08 | Klippan Nv | Belteslas med lett frigorbar sperr |
| AT397200B (de) * | 1988-06-03 | 1994-02-25 | Birkmayer Joerg Ddr | Verwendung von selenmethionin zur herstellung eines arzneimittels |
| IL110139A0 (en) | 1993-06-28 | 1994-10-07 | Howard Foundation | Pharmaceutically-active antioxidants |
| US5358720A (en) | 1993-10-22 | 1994-10-25 | Koppel Richard M | Treatment of arthritic conditions |
| HUT72422A (en) | 1994-04-20 | 1996-04-29 | Beres Export Import Rt | Aquous concentrate and process for its preparation |
| FR2737205B1 (fr) * | 1995-07-26 | 1997-09-12 | Oreal | Nouveaux derives de n,n'-di(aralkyl) n,n'-di(2-azaaralkyl) alkylene diamine et leur utilisation dans des compositions pharmaceutiques et cosmetiques |
| US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| AU7222598A (en) * | 1997-04-29 | 1998-11-24 | Scotia Holdings Plc | Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants |
| US6399114B2 (en) | 2000-05-26 | 2002-06-04 | C & D Foreman, Inc. | Nutritional system for nervous system disorders |
| DK1163904T3 (da) | 2000-06-16 | 2006-08-14 | Matthias Dr Med Rath | Sammensætning til forebyggelse af glat muskelsygdom, der omfatter ascorbat, arginin og magnesium |
-
2002
- 2002-02-07 GB GBGB0202900.7A patent/GB0202900D0/en not_active Ceased
-
2003
- 2003-02-04 JP JP2003565495A patent/JP2005525329A/ja active Pending
- 2003-02-04 NZ NZ534304A patent/NZ534304A/en not_active IP Right Cessation
- 2003-02-04 WO PCT/GB2003/000490 patent/WO2003066071A1/en not_active Ceased
- 2003-02-04 AU AU2003244454A patent/AU2003244454A1/en not_active Abandoned
- 2003-02-04 EP EP03737361A patent/EP1478374A1/en not_active Ceased
- 2003-02-06 TW TW092102377A patent/TW200404558A/zh unknown
- 2003-02-07 US US10/359,552 patent/US6919330B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525329A5 (enExample) | ||
| DK1471890T3 (da) | Farmaceutisk doseringsform til mukös afgivelse | |
| JP2010525050A5 (enExample) | ||
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| SI9200403B (en) | New combination of a bronchodilator and a steroidal antiinflammatory drug for treatment of respiratory disorders as well as its use and preparation thereof | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| JP2005515966A5 (enExample) | ||
| BG100933A (en) | Polymer coated tablets comprising amoxycilin and clavulanate | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| MY144021A (en) | Pharmaceutical delivery system | |
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
| EP1393734A4 (en) | DRUG AGAINST DARMER DISEASES | |
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| WO2004112838A3 (en) | Codrugs of diclofenac | |
| JP2002540148A5 (enExample) | ||
| US20150352038A1 (en) | A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder | |
| WO2007127683A3 (en) | Administration of agonist-antagonist in opioid-dependent patients | |
| JP2016513694A (ja) | ビタミンｂ１２欠乏症を治療する方法 | |
| PL1778209T3 (pl) | Sposoby i kompozycje do doustnego dostarczania FTS | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| CA2474703A1 (en) | Therapeutic agent of glaucoma comprising bunazosin and prostaglandins |